Effect of "Nicotinamide Mononucleotide" (NMN) on Cardiometabolic Function (NMN)

This is an interventional basic science trial for Glucose Metabolism Disorders Read More

Inclusion Criteria:

• Postmenopausal women 55-75 years old
• BMI 25.0-44.9 kg/m²
• Fasting plasma glucose concentration ≥100 mg/dl, OGTT 2 hour glucose ≥ 140 mg/dl, HbA1C ≥5.7%, or HOMA-IR ≥2.5

Exclusion Criteria:

• Diabetes
• Premenopausal or menopause <1 year
• Persons who have received hormone replacement therapy within the past 6 months
• Persons who take vitamin B supplementation and are not willing to discontinue supplementation for 3 weeks before and during the entire study period.
• Structured exercise: ≥75 min/wk of vigorous exercise (e.g., jogging, activity that causes heavy breathing and sweating) or ≥150 min/wk of low intensity physical activity (e.g., brisk walking).
• Unstable weight (>3% change during the last 2 months before entering the study)
• Significant organ system dysfunction or disease
• Present cancer or history of cancer that has been in remission for <5 years
• Polycystic ovary syndrome
• Major psychiatric illness
• Use of medications known to affect study outcome measures (e.g., steroid) or increase the risk of study procedures (e.g., anticoagulants) that cannot be temporarily discontinued for the study
• Metal implants
• Smokes cigarettes
• Persons who consume >14 units of alcohol per week
• Unable or unwilling to follow the study protocol or who, for any reason, is considered an inappropriate candidate for the study by the research team.